Shanghai Conant Optical Co Ltd
Shanghai Conant Optical Co Ltd designs, develops, and sells optical products and systems for the medical and industrial markets.
Business. Shanghai Conant Optical Co Ltd (2276.HK) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm is headquartered in Shanghai and is primarily listed on the Hong Kong Stock Exchange. It generates revenue through the sale of medical products, though specific operating segments and geographic breakdowns are not disclosed.
Analyst recommendations
11 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Shanghai Conant Optical Co Ltd (2276.HK) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm is headquartered in Shanghai and is primarily listed on the Hong Kong Stock Exchange. It generates revenue through the sale of medical products, though specific operating segments and geographic breakdowns are not disclosed.
The company has a market capitalization of 23.19 billion CNY, with a current market price of 45.98 CNY per share. The capital structure is undiluted, as the number of basic and diluted shares outstanding is identical at 504.3 million. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
Profitability and return metrics are not available in the valuation snapshot, but the company operates in the medical equipment and supplies industry, where key performance indicators include gross margins, R&D investment, and market share in high-growth segments. Analysts have assigned a mean price target of 68.00 CNY, suggesting a potential upside of 47.7% from the current market price.
The company's geographic and segment exposure is not disclosed in the available data, but the industry is characterized by high concentration in developed markets and a growing demand for diagnostic and therapeutic equipment. Analysts have issued 4 strong-buy and 7 buy recommendations, with no hold or sell ratings, indicating strong near-term confidence in the company's growth prospects.
The company's growth trajectory is not quantified in the input data, but the industry is expected to benefit from aging populations and increased healthcare spending in Asia-Pacific markets. Analysts project a wide range of price targets, from 50.00 to 88.00 CNY, with a median of 67.50 CNY, suggesting a consensus for significant upside potential.
Dilution risk is currently low, as the number of basic and diluted shares is the same, and no recent equity issuance or ATM/shelf registration is disclosed in the source documents. However, the absence of balance-sheet data limits the ability to assess credit risk or liquidity pressures.
Recent events include the publication of analyst price targets and recommendations, with a mean recommendation score of 1.64, indicating a strong buy consensus. No recent filings or earnings transcripts are available in the input data to provide further insight into the company's operational performance or strategic direction.
- Analysts project a 47.7% upside from the current market price, with a median price target of 67.50 CNY.
- The company has no dilution risk in the near term, as basic and diluted shares are equal.
- Strong buy sentiment is evident, with 4 strong-buy and 7 buy ratings from analysts.
- Liquidity risk could not be assessed due to missing balance-sheet data.
- The company operates in a high-growth industry with demand driven by aging populations and healthcare spending in Asia-Pacific.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue ¥2.19B, +6,1% YoY; Operating income +26,7% YoY.
- ▍Revenue ¥2.19B, +6,1% YoY
- ▍Operating income +26,7% YoY
- ▍Net income +30,2% YoY
- ▍Free cash flow +32,8% YoY
- ▍Net margin 25.5%
Revenue ¥2.06B, +17,1% YoY; Operating income +25,4% YoY.
- ▍Revenue ¥2.06B, +17,1% YoY
- ▍Operating income +25,4% YoY
- ▍Net income +31,0% YoY
- ▍Free cash flow −21,8% YoY
- ▍Net margin 20.8%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 1,42 |
| Revenue | —no estimate | —no estimate | 2,5B CNY |
| Operating income | —no estimate | —no estimate | 781,8M CNY |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Shanghai Conant Optical Co Ltd Market data — financials · 2026-05-26
- Shanghai Conant Optical Co Ltd Market data — analyst estimates · 2026-05-26